NASDAQ:DXCMDexCom Stock Price, Forecast & News

DexCom's stock was trading at $252.42 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, DXCM stock has increased by 68.4% and is now trading at $425.16.
View which stocks have been most impacted by COVID-19.

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 5 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for DexCom.

DexCom is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for DexCom.

DexCom, Inc. (NASDAQ:DXCM) issued its quarterly earnings data on Tuesday, July, 28th. The medical device company reported $0.79 EPS for the quarter, beating the consensus estimate of $0.31 by $0.48. The medical device company earned $451.80 million during the quarter, compared to analysts' expectations of $415.21 million. DexCom had a return on equity of 29.01% and a net margin of 11.93%. DexCom's quarterly revenue was up 34.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.08 earnings per share.
View DexCom's earnings history.

DexCom issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, July, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.85-1.85 billion, compared to the consensus revenue estimate of $1.8 billion.

21 brokers have issued 12 month target prices for DexCom's shares. Their forecasts range from $190.00 to $500.00. On average, they anticipate DexCom's stock price to reach $393.20 in the next year. This suggests that the stock has a possible downside of 7.5%.
View analysts' price targets for DexCom.

Media coverage about DXCM stock has trended somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. DexCom earned a news sentiment score of -1.8 on InfoTrie's scale. They also assigned headlines about the medical device company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
View the latest news about DexCom.

Some companies that are related to DexCom include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Stryker (SYK), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR), Steris (STE) and ABIOMED (ABMD).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), Alibaba Group (BABA), Paypal (PYPL), salesforce.com (CRM), Netflix (NFLX), Trade Desk (TTD), Advanced Micro Devices (AMD), Shopify (SHOP), Square (SQ) and ServiceNow (NOW).

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

DexCom's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.73%), Mint Tower Capital Management B.V. (8.20%), Jennison Associates LLC (2.88%), Blair William & Co. IL (1.12%), Federated Hermes Inc. (0.61%) and Gilder Gagnon Howe & Co. LLC (0.53%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman and Steven Robert Pacelli.
View institutional ownership trends for DexCom.

DXCM stock was sold by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank, Holocene Advisors LP, Columbus Circle Investors, Ardevora Asset Management LLP, Frontier Capital Management Co. LLC, Sumitomo Mitsui Trust Holdings Inc., Macquarie Group Ltd., and Gilder Gagnon Howe & Co. LLC. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barbara Kahn, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman, and Steven Robert Pacelli.
View insider buying and selling activity for DexCom.

DXCM stock was bought by a variety of institutional investors in the last quarter, including Mint Tower Capital Management B.V., Vanguard Group Inc., Coatue Management LLC, Principal Financial Group Inc., New York State Teachers Retirement System, Jackson Square Partners LLC, Bessemer Group Inc., and Jennison Associates LLC.
View insider buying and selling activity for DexCom.

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DXCM stock can currently be purchased for approximately $425.16.

DexCom has a market capitalization of $40.71 billion and generates $1.48 billion in revenue each year. The medical device company earns $101.10 million in net income (profit) each year or $1.84 on an earnings per share basis. DexCom employs 3,900 workers across the globe.

The official website for DexCom is www.dexcom.com.

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]